- Home
- MTNB vs ONCO Comparison
MTNB vs ONCO Comparison
Compare MTNB & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | ONCO |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 3.0M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTNB | ONCO |
|---|---|---|
| Price | $2.74 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 341.7K | ★ 6.7M |
| Earning Date | 08-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.09 |
| 52 Week High | $3.16 | $798.00 |
Technical Indicators
Market Signals| Indicator | MTNB | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 74.24 | 39.52 |
| Support Level | $0.39 | $0.09 |
| Resistance Level | N/A | $1.09 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 87.33 | 1.69 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.